Skip to main content

Demyelinating diseases

Section edited by Francesco Patti

This section covers all types of demyelinating diseases. Topics of interest include, but are not limited to, multiple sclerosis, neuroimmunology, systemic lupus, vasculitis, lymphoma, and myelitis.

Page 4 of 7

  1. Recent studies suggest that cortical lesions in multiple sclerosis (MS) substantially contribute to clinical disease severity. The present study aimed at investigating clinical, neuroanatomical, and cognitive ...

    Authors: Olivia Geisseler, Tobias Pflugshaupt, Ladina Bezzola, Katja Reuter, David Weller, Bernhard Schuknecht, Peter Brugger and Michael Linnebank

    Citation: BMC Neurology 2016 16:204

    Content type: Research article

    Published on:

  2. Leber’s hereditary optic neuropathy (LHON) co-occuring with multiple sclerosis-like disease (LHON-MS) is suggested to be a separate disease entity denoted Harding’s disease. Little is known about the response ...

    Authors: Trygve Holmøy, Antonie G. Beiske, Svetozar Zarnovicky, Aija Zuleron Myro, Egil Røsjø and Emilia Kerty

    Citation: BMC Neurology 2016 16:197

    Content type: Case report

    Published on:

  3. In the US, the approved multiple sclerosis (MS) oral disease-modifying therapies (ODMTs) are fingolimod (FTY), teriflunomide (TFN), and dimethyl fumarate (DMF). FTY and TFN are recommended with once-daily dose...

    Authors: Tara Nazareth, Howard S. Friedman, Prakash Navaratnam, Denise A. Herriott, John J. Ko, Peri Barr and Rahul Sasane

    Citation: BMC Neurology 2016 16:187

    Content type: Research article

    Published on:

  4. Since the application of MRI scanning to the diagnosis and treatment of multiple sclerosis, it has been recognized that only a small fraction of lesions seen on MRI scans produce recognizable symptoms or neuro...

    Authors: Stanley Cohan, Chiayi Chen, Elizabeth Baraban, Tamela Stuchiner and Lois Grote

    Citation: BMC Neurology 2016 16:184

    Content type: Research article

    Published on:

  5. Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients’ perception of treatment efficacy. T...

    Authors: Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Klaus Hechenbichler and Michael Hecker

    Citation: BMC Neurology 2016 16:181

    Content type: Research article

    Published on:

  7. Guillain-Barré syndrome is an acquired polyradiculo-neuropathy, often preceded by an antecedent event. It is a monophasic disease but a recurrence rate of 1–6 % is documented in a subset group of patients. Pat...

    Authors: Sonali Sihindi Chapa Gunatilake, Rohitha Gamlath and Harith Wimalaratna

    Citation: BMC Neurology 2016 16:161

    Content type: Case report

    Published on:

  8. Patients with multiple sclerosis (MS) or Crohn’s disease (CD) being treated with natalizumab (Tysabri®, Biogen) who are planning to become pregnant or discover they are pregnant after exposure to natalizumab a...

    Authors: Susan Friend, Sandra Richman, Gary Bloomgren, Lynda M. Cristiano and Madé Wenten

    Citation: BMC Neurology 2016 16:150

    Content type: Research article

    Published on:

  9. Amongst Sardinians the human leukocyte antigen (HLA) DRB1-DQB1 haplotypes *15:02-*06:01, *16:01-*05:02, *14:01-4-*05:03 are protective for multiple sclerosis (MS), while *13:03-*03:01, *04:05-*03:01, *03:01-*0...

    Authors: J. Frau, D. Cossu, C. Sardu, G. Mameli, G. Coghe, L. Lorefice, G. Fenu, S. Tranquilli, L. A. Sechi, M. G. Marrosu and E. Cocco

    Citation: BMC Neurology 2016 16:148

    Content type: Research article

    Published on:

  10. Comprehensive epidemiologic data for multiple sclerosis (MS) in Poland are limited. The aim of this cross-sectional population-based study was to determine the incidence and prevalence of MS in the Swietokrzys...

    Authors: Waldemar Brola, Piotr Sobolewski, Stanisław Flaga, Małgorzata Fudala, Wiktor Szczuchniak, Jan Stoiński, Anita Rosołowska, Jacek Wójcik, Katarzyna Kapica-Topczewska and Danuta Ryglewicz

    Citation: BMC Neurology 2016 16:134

    Content type: Research article

    Published on:

  13. Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy of dacliz...

    Authors: Ralf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, Krzysztof Selmaj, Eva Havrdova, Dusan Stefoski, Till Sprenger, Xavier Montalban, Stanley Cohan, Kimberly Umans, Steven J. Greenberg, Gulden Ozen and Jacob Elkins

    Citation: BMC Neurology 2016 16:117

    Content type: Research article

    Published on:

  14. Alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, is licensed in Europe since October 2013 as treatment for adult patients with active relapsing-remitting multip...

    Authors: Tjalf Ziemssen, Ulrich Engelmann, Sigbert Jahn, Alexandra Leptich, Raimar Kern, Lina Hassoun and Katja Thomas

    Citation: BMC Neurology 2016 16:109

    Content type: Study protocol

    Published on:

  15. To examine whether past and current reserve-related activities make the brain less susceptible to MS pathology (i.e., lesions or disease-related atrophy).

    Authors: Carolyn E. Schwartz, Michael G. Dwyer, Ralph Benedict, Bianca Weinstock-Guttman, Niels P. Bergsland, Jei Li, Murali Ramanathan and Robert Zivadinov

    Citation: BMC Neurology 2016 16:108

    Content type: Research article

    Published on:

  16. This retrospective analysis explored prognostic factors associated with a benign multiple sclerosis (BMS) disease course at baseline and over the 4-year follow-up.

    Authors: Robert Zivadinov, Diane L. Cookfair, Lauren Krupp, Aaron E. Miller, Neil Lava, Patricia K. Coyle, Andrew D. Goodman, Burk Jubelt, Michael Lenihan, Joseph Herbert, Malcolm Gottesman, David H. Snyder, Brian R. Apatoff, Barbara E. Teter, Allan B. Perel, Frederick Munschauer…

    Citation: BMC Neurology 2016 16:102

    Content type: Research article

    Published on:

  17. Patients suffering from several neurologic disorders may bear the “stigma” of their disease, being disqualified from full social acceptance. Although stigma is considered to be present in Multiple Sclerosis (M...

    Authors: Maria Anagnostouli, Serafeim Katsavos, Artemios Artemiadis, Markos Zacharis, Paraskevi Argyrou, Ilia Theotoka, Fotini Christidi, Ioannis Zalonis and Ioannis Liappas

    Citation: BMC Neurology 2016 16:101

    Content type: Research article

    Published on:

  18. Natalizumab provides rapid and high-efficacy control of multiple sclerosis disease activity with long-term stabilization. However, the benefits of the drug are countered by a risk of developing progressive mul...

    Authors: Tjalf Ziemssen, Achim Gass, Jens Wuerfel, Antonios Bayas, Björn Tackenberg, Volker Limmroth, Ralf Linker, Mathias Mäurer, Judith Haas, Martin Stangel, Matthias Meergans, Olof Harlin and Hans-Peter Hartung

    Citation: BMC Neurology 2016 16:98

    Content type: Study protocol

    Published on:

  19. In neuromyelitis optica (NMO), one of the underlying pathogenic mechanisms is the formation of antigen-antibody complexes which can trigger an inflammatory response by inducing the infiltration of neutrophils ...

    Authors: Tao Yang, Su Wang, Qi Zheng, Lei Wang, Qian Li, Mingyan Wei, Zongpan Du and Yongping Fan

    Citation: BMC Neurology 2016 16:96

    Content type: Research article

    Published on:

  20. Functional biomarkers able to identify multiple sclerosis (MS) patients at high risk of fast disability progression are lacking. The aim of this study was to evaluate the ability of multimodal (upper and lower...

    Authors: Xavier Giffroy, Nathalie Maes, Adelin Albert, Pierre Maquet, Jean-Michel Crielaard and Dominique Dive

    Citation: BMC Neurology 2016 16:83

    Content type: Research article

    Published on:

  21. In people with multiple sclerosis (MS) disabilities and limitations may negatively affect self-efficacy. Lowered self-efficacy has been associated with decreases in health-related quality of life, physical act...

    Authors: Peter Joseph Jongen, Marco Heerings, Rob Ruimschotel, Astrid Hussaarts, Silvia Evers, Lotte Duyverman, Joyce Valkenburg-Vissers, Job Cornelissen, Michel Bos, Maarten van Droffelaar, Wim A. Lemmens, Rogier Donders, Anneke van der Zande and Leo H. Visser

    Citation: BMC Neurology 2016 16:81

    Content type: Study protocol

    Published on:

  22. The present study was carried out to evaluate cerebral perfusion in multiple sclerosis (MS) patients with a moderate to severe stage of disease. Some patients underwent hyperbaric oxygen therapy (HBOT) and bra...

    Authors: Mina Taghizadeh Asl, Reza Nemati, Negar Chabi, Hooman Salimipour, Iraj Nabipour and Majid Assadi

    Citation: BMC Neurology 2016 16:79

    Content type: Research article

    Published on:

  23. Andrographis paniculata (A. paniculata), a medicinal plant, has shown anti-inflammatory, neuroprotective and antifibrotic effects in animal models as well as clinical efficacy in different studies, including an a...

    Authors: J. C. Bertoglio, M. Baumgartner, R. Palma, E. Ciampi, C. Carcamo, D. D. Cáceres, G. Acosta-Jamett, J. L. Hancke and R. A. Burgos

    Citation: BMC Neurology 2016 16:77

    Content type: Research article

    Published on:

  24. Accumulating evidences from experimental, epidemiologic and clinical studies support the potential linkage between poor vitamin D status and the risk of developing Multiple Sclerosis (MS), as well as, an adver...

    Authors: Soodeh Razeghi Jahromi, Mohammad Ali Sahraian, Mansoureh Togha, Behnaz Sedighi, Vahid Shayegannejad, Alireza Nickseresht, Shahriar Nafissi, Niayesh Mohebbi, Nastran Majdinasab, Mohsen Foroughipour, Masoud Etemadifar, Nahid Beladi Moghadam, Hormoz Ayramlou, Fereshteh Ashtari and Shekoofe Alaie

    Citation: BMC Neurology 2016 16:76

    Content type: Debate

    Published on:

  26. Multiple sclerosis (MS) is an incurable, unpredictable but typically progressive neurological condition. It is the most common cause of neurological disability in young adults. Within 15 years of diagnosis, ap...

    Authors: J. A. Freeman, W. Hendrie, S. Creanor, L. Jarrett, A. Barton, C. Green, J. Marsden, E. Rogers and J. Zajicek

    Citation: BMC Neurology 2016 16:62

    Content type: Study protocol

    Published on:

  27. The management of multiple sclerosis (MS) is rapidly changing by the introduction of new and more effective disease-modifying agents. The importance of risk stratification was confirmed by results on disease p...

    Authors: Gustavo Saposnik, Angel Perez Sempere, Roula Raptis, Daniel Prefasi, Daniel Selchen and Jorge Maurino

    Citation: BMC Neurology 2016 16:58

    Content type: Study protocol

    Published on:

  30. Reversible splenial lesion syndrome (RESLES) is a disorder radiologically characterized by reversible lesion in the splenium of the corpus callosum (SCC). Most of patients with RESLES associated with encephali...

    Authors: Yuanzhao Zhu, Junjun Zheng, Ling Zhang, Zhenguo Zeng, Min Zhu, Xiaobin Li, Xiaoliang Lou, Hui Wan and Daojun Hong

    Citation: BMC Neurology 2016 16:49

    Content type: Research article

    Published on:

  31. Leakage of the blood–brain barrier (BBB) is a common pathological feature in multiple sclerosis (MS). Following a breach of the BBB, albumin, the most abundant protein in plasma, gains access to CNS tissue whe...

    Authors: Steven M. LeVine

    Citation: BMC Neurology 2016 16:47

    Content type: Review

    Published on:

  32. Alemtuzumab (Lemtrada®) is a newly approved therapeutic agent for relapsing-remitting multiple sclerosis (RRMS). In previous phase II and III clinical trials, alemtuzumab has proven superior efficacy to subcut...

    Authors: Tobias Ruck, Ali Maisam Afzali, Karl-Friedrich Lukat, Maria Eveslage, Catharina C. Gross, Steffen Pfeuffer, Stefan Bittner, Luisa Klotz, Nico Melzer, Heinz Wiendl and Sven G. Meuth

    Citation: BMC Neurology 2016 16:34

    Content type: Study protocol

    Published on:

  33. There is limited knowledge regarding how depressive symptoms and a cluster of specific mood symptoms in people with multiple sclerosis (MS) vary over time and how they are influenced by contributing factors. T...

    Authors: Sverker Johansson, Kristina Gottberg, Marie Kierkegaard and Charlotte Ytterberg

    Citation: BMC Neurology 2016 16:32

    Content type: Research article

    Published on:

  34. People with multiple sclerosis (MS) are increasingly using the Internet in the daily management of their condition. They search for high-quality information in plain language, from independent sources, based o...

    Authors: Cinzia Colombo, Graziella Filippini, Anneliese Synnot, Sophie Hill, Roberta Guglielmino, Silvia Traversa, Paolo Confalonieri, Paola Mosconi and Irene Tramacere

    Citation: BMC Neurology 2016 16:30

    Content type: Research article

    Published on:

  35. Leukoencephalopathy with calcifications and cysts (LCC or Labrune disease) is a relatively recently defined and exceptionally rare disease in which parenchymal cysts and calcifications within a widespread leuk...

    Authors: C. Stephani, S. Pfeifenbring, A. Mohr and C. Stadelmann

    Citation: BMC Neurology 2016 16:19

    Content type: Case report

    Published on:

  36. Multiple Sclerosis has a great impact on psychological functioning of patients and can be associated with various mental health disorders and symptoms. The most prevalent one is depression, which ranges from 1...

    Authors: Sara Carletto, Martina Borghi, Diana Francone, Francesco Scavelli, Gabriella Bertino, Marco Cavallo, Simona Malucchi, Antonio Bertolotto, Francesco Oliva and Luca Ostacoli

    Citation: BMC Neurology 2016 16:7

    Content type: Study protocol

    Published on:

  37. The evidence on the use of the oral dimethyl-fumarate after the discontinuation of treatment with natalizumab in people with Multiple Sclerosis is still little. Natalizumab discontinuation may induce the recur...

    Authors: Francesco Patti, Carmela Leone and Mario Zappia

    Citation: BMC Neurology 2015 15:252

    Content type: Case report

    Published on:

  39. Cognitive deficits are common in multiple sclerosis (MS) and require continuous monitoring. In routine examinations, screening instruments such as the Brief Repeatable Battery (BRB) may serve this purpose. It ...

    Authors: Sascha Hansen, Jana Muenssinger, Simona Kronhofmann, Stefan Lautenbacher, Patrick Oschmann and Philipp M Keune

    Citation: BMC Neurology 2015 15:246

    Content type: Research article

    Published on:

  40. Positron emission tomography (PET) images with amyloid tracers show normal uptake in healthy white matter, which suggests that amyloid tracers are potentially useful for studying such white matter diseases as ...

    Authors: Jordi A. Matías-Guiu, María Nieves Cabrera-Martín, Jorge Matías-Guiu, Celia Oreja-Guevara, Cristina Riola-Parada, Teresa Moreno-Ramos, Juan Arrazola and José Luis Carreras

    Citation: BMC Neurology 2015 15:243

    Content type: Research article

    Published on:

  41. Interferon (IFN) beta-1a is an approved treatment for relapsing remitting multiple sclerosis (RRMS) and has been examined for use in secondary progressive multiple sclerosis (SPMS). However, no information reg...

    Authors: Michael Gurevich, Gadi Miron, Rina Zilkha Falb, David Magalashvili, Mark Dolev, Yael Stern and Anat Achiron

    Citation: BMC Neurology 2015 15:240

    Content type: Research article

    Published on:

  43. We aimed to determine the association of clinical and routine cerebrospinal fluid biochemical markers (total protein, IgG index and oligoclonal bands) with disability in multiple sclerosis and whether these bi...

    Authors: Madlyne Becker, Clotilde Latarche, Emilie Roman, Marc Debouverie, Catherine Malaplate-Armand and Francis Guillemin

    Citation: BMC Neurology 2015 15:79

    Content type: Research article

    Published on:

  44. Epidemiological studies describe a latitude gradient for increased MS prevalence and a preponderance of disease in Caucasian individuals. However, individuals from other ethnic backgrounds and low-risk regions...

    Authors: Richard S Nicholas, Vassiliki Kostadima, Maya Hanspal, Benjamin R Wakerley, Ruhena Sergeant, Saskia Decuypere, Omar Malik, Rosemary J Boyton and Daniel M Altmann

    Citation: BMC Neurology 2015 15:72

    Content type: Research article

    Published on:

  45. Decision-making is an essential function of everyday life. Decision-making under explicit risk requires developing advantageous decision strategies based on fixed outcomes (e.g., probabilities of winning or lo...

    Authors: Ashley D Radomski, Christopher Power, Scot E Purdon, Derek J Emery, Gregg Blevins, Kenneth G Warren and Esther Fujiwara

    Citation: BMC Neurology 2015 15:61

    Content type: Research article

    Published on:

  46. Neuropsychological batteries are infrequently used to assess cognitive impairment in multiple sclerosis because they are time-consuming and require trained personnel. The Symbol Digit Modalities Test (SDMT) is...

    Authors: Mariana López-Góngora, Luis Querol and Antonio Escartín

    Citation: BMC Neurology 2015 15:40

    Content type: Research article

    Published on:

  47. Pol III-related leukodystrophies, including 4H leukodystrophy, are recently recognized disorders that comprise hypomyelination and various neurologic and non-neurologic clinical manifestations. We report the u...

    Authors: Ana Potic, Vera Popovic, Jelena Ostojic, Sandra Pekic, Dusko Kozic, Kether Guerrero, Raphael Schiffmann and Geneviève Bernard

    Citation: BMC Neurology 2015 15:22

    Content type: Case report

    Published on:

  48. People with multiple sclerosis (PwMS) endure walking limitations. To address this restriction, various physical rehabilitation programs have been implemented with no consensus regarding their efficacy. Our obj...

    Authors: Alon Kalron, Dalia Nitzani, David Magalashvili, Mark Dolev, Shay Menascu, Yael Stern, Uri Rosenblum, Diana Pasitselsky, Lior Frid, Gabi Zeilig, Caroline Barmatz, Uri Givon and Anat Achiron

    Citation: BMC Neurology 2015 15:21

    Content type: Research article

    Published on:

  49. Unusual presentations of multiple sclerosis (MS) at onset may post a diagnostic dilemma to the treating neurologists. Spinal myoclonus is rare in MS and may lead to perform extensive investigations to rule out...

    Authors: Raed Abdullah Alroughani, Samar Farouk Ahmed, Riyadh Ahmed Khan and Jasem Yousef Al-Hashel

    Citation: BMC Neurology 2015 15:15

    Content type: Case report

    Published on:

  50. Subcutaneous peginterferon beta-1a provided clinical benefits at Year 1 (placebo-controlled period) of the 2-Year Phase 3 ADVANCE study in relapsing-remitting multiple sclerosis (RRMS). Here we report the effe...

    Authors: Douglas L Arnold, Peter A Calabresi, Bernd C Kieseier, Sarah I Sheikh, Aaron Deykin, Ying Zhu, Shifang Liu, Xiaojun You, Bjoern Sperling and Serena Hung

    Citation: BMC Neurology 2014 14:240

    Content type: Research article

    Published on:

Submit manuscript

Follow

2019 Journal Metrics

BMC Neurology

ISSN: 1471-2377

Contact us